Navigation Links
NPS Pharmaceuticals Reports 2007 Financial Results
Date:3/13/2008

ceuticals is developing specialty therapeutics for gastrointestinal and endocrine disorders with high unmet medical need. The company is currently advancing two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is available at http://www.npsp.com.

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to NPS's business include, but are not limited to, the risk of successfully executing its preclinical and clinical studies and gaining marketing approvals for GATTEX and NPSP558, the risks associated with the company's auction-rate securities, the risk that the steps NPS has taken or is taking to address the material weakness will be adequate or that future material weaknesses or control deficiencies will be identified, as well as other factors expressed in NPS's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.


'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
3. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
4. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
5. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
8. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
9. Onyx Pharmaceuticals to Present at Cowen and Company Health Care Conference
10. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
11. VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 ... services company for clinical trials, announced today it ... Solutions, LLC. Clinverse’s ClinPay® FLS eClinical commerce ... payment process. SpendMD ™, Aggregate Spend ... solution for tracking and reporting transfer of value ...
(Date:5/21/2013)... York , May 21, 2013 ... Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and ... IVD Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and ... billion in 2011 and is expected to grow at ... reach an estimated value of USD 4.7 billion in ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Many have ... as contributor to acne. Recently physicians from Clinical ... mental stress on the skin, and suggested using ... reduce the chemicals produced from stress that cause acne. ... the negative feelings acne brings about, stress causes changes ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI , ... develops,and commercializes differentiated products for patients worldwide, ... disclosed in accordance with,Rule 26 of the ... the "Shareholder,Information/Rule 26 Disclosures" section on the ...
... may seem low on the priority scheme. Alternately, it may ... available. Neither is true. , ,The board of directors ... management. Eventually the board should become a entity that promotes, ... But at the very start, the only guarantee is that ...
... Wisconsins economy needs new thoughts, new processes, and new innovations, ... New Economy is an old worn-out phase used in Silicon ... lies, lavish spending and corruption as well as cute, but ... Wisconsin Economy will unfold in a Real-Time Economy, in which ...
Cached Biology Technology:YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26 2Board Pieces 2Board Pieces 3Board Pieces 4Wisconsins Real-Time" Economy 2Wisconsins Real-Time" Economy 3Wisconsins Real-Time" Economy 4
(Date:5/21/2013)... experts , Where? Copenhagen, Denmark: Bella ... June 2013 , Why? An ... and policy developments, manufacturing and installation, drawing on leading ... its 2013 edition from a record of more than ... than 240 plenary and oral presentations, more than 460 ...
(Date:5/21/2013)... genes function without changing the underlying DNA sequence, ... pregnant women during any trimester, potentially providing a ... after giving birth, and an opportunity to intervene ... the small study involving 52 pregnant women are ... . , "Postpartum depression can be harmful to ...
(Date:5/20/2013)... Little is known about the effect of physical education ... Cornell University finds that increasing the amount of time ... probability of obesity. , The study represents some of ... on youth obesity, and is forthcoming in the ... version of the study can be viewed at: ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
... Agricultural Research and Development, Neiker-Tecnalia, have undertaken a study ... pathogens, which has confirmed the importance of continous surveillance ... in the Basque Country and has revealed an increase ... in the average winter temperatures. It has also pointed ...
... A break in the two chromosomes has given scientists ... puberty, Medical College of Georgia researchers report. It,s ... puberty have no sense of smell, said Dr. Lawrence ... Endocrinology, Infertility and Genetics. The WRD11 gene interacts ...
... (BRONX, NY) The National Institute of General Medical ... Medicine of Yeshiva University a five-year, $30 million ... of biomedically important proteins. "Determining the structures of ... in normal biological processes as well as in disease ...
Cached Biology News:Neiker-Tecnalia confirms need to undertake epidemiological monitoring programs for ticks 2Neiker-Tecnalia confirms need to undertake epidemiological monitoring programs for ticks 3Chromosomal break gives scientists a break in finding new puberty gene 2Chromosomal break gives scientists a break in finding new puberty gene 3Einstein receives $30 million to study protein form and function 2Einstein receives $30 million to study protein form and function 3Einstein receives $30 million to study protein form and function 4
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse P-Selectin/CD62P MAb (Clone 127933)...
Recombinant Rat Leptin, Ultra Pure...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: